EcoDrugPlus

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSDNOG00000049736
Gene Symbol: NR3C2
4 Cross references
214 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSDNOG00000037559
Gene Symbol: NOD2
4 Cross references
167 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSDNOG00000046525
Gene Symbol: OPRD1
4 Cross references
254 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSDNOG00000019938
Gene Symbol: OPRK1
2 Cross references
264 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSDNOG00000000202
Gene Symbol: OPRM1
2 Cross references
215 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSDNOG00000001561
Gene Symbol: OPRL1
4 Cross references
202 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSDNOG00000033285
Gene Symbol: OXTR
2 Cross references
265 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSDNOG00000046152
Gene Symbol: PAK4
2 Cross references
160 Possible Orthologues:

Pancreatic Alpha-Amylase

Ensembl ID : ENSDNOG00000039299
Gene Symbol: LOC101427906
3 Cross references
207 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSDNOG00000041987
Gene Symbol: PTH1R
2 Cross references
199 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSDNOG00000009243
Gene Symbol: PPARA
2 Cross references
455 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSDNOG00000038434
Gene Symbol: PPARD
2 Cross references
420 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).